Page last updated: 2024-09-04

nepafenac and Alloxan Diabetes

nepafenac has been researched along with Alloxan Diabetes in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (100.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Ball, SL; Bingaman, DP; Du, Y; Jamison, JA; Kern, TS; Kim, M; Miller, CM; Mohr, S; Zheng, L	1

Other Studies

1 other study(ies) available for nepafenac and Alloxan Diabetes

Article	Year
Topical administration of nepafenac inhibits diabetes-induced retinal microvascular disease and underlying abnormalities of retinal metabolism and physiology. Diabetes, 2007, Volume: 56, Issue:2 Topics: Administration, Topical; Animals; Anti-Inflammatory Agents; Benzeneacetamides; Caspase 3; Caspase 6; Cyclooxygenase 2; Diabetes Mellitus, Experimental; Diabetic Retinopathy; Dinoprostone; Evoked Potentials, Visual; Inflammation; Male; Matrix Metalloproteinase 2; Nitric Oxide; Ophthalmic Solutions; Phenylacetates; Random Allocation; Rats; Rats, Inbred Lew; Retina; Retinal Vessels; Streptozocin; Superoxides; Vascular Endothelial Growth Factors	2007

Article

Year

Topical administration of nepafenac inhibits diabetes-induced retinal microvascular disease and underlying abnormalities of retinal metabolism and physiology.

Diabetes, 2007, Volume: 56, Issue:2

Topics: Administration, Topical; Animals; Anti-Inflammatory Agents; Benzeneacetamides; Caspase 3; Caspase 6; Cyclooxygenase 2; Diabetes Mellitus, Experimental; Diabetic Retinopathy; Dinoprostone; Evoked Potentials, Visual; Inflammation; Male; Matrix Metalloproteinase 2; Nitric Oxide; Ophthalmic Solutions; Phenylacetates; Random Allocation; Rats; Rats, Inbred Lew; Retina; Retinal Vessels; Streptozocin; Superoxides; Vascular Endothelial Growth Factors

2007